skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Fast neutrons and misonidazole for malignant astrocytomas

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

Twenty-five patients with proven malignant supratentorial astrocytomas were entered into a Phase I/II study of misonidazole combined with neutron radiation at Fermilab Neutron Therapy Facility (NTF) between August 1979 and April 1981. The main objectives were to determine tissue tolerance in terms of acute and late effects, and to estimate tumor clearance and survival rates. The total dose was 18.0 Gy given in weekly fractions of 3.0 Gy over 39 days. Four hours before each irradiation, 2.5 gm/m/sup 2/ misonidazole was administered orally. The median survival for the whole group was 12.0 months; 25% were alive at 18 months with some neurological compromise. Acute toxicity was within tolerable limits. Details of toxicity and tissue analysis from post mortems and second craniotomy samples are presented.

Research Organization:
Fermilab Neutron Therapy Facility, Batavia, IL
OSTI ID:
5436470
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 11:4
Country of Publication:
United States
Language:
English

Similar Records

Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna study group
Conference · Sat Sep 01 00:00:00 EDT 1984 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5436470

Large fraction radiotherapy plus misonidazole for treatment of advanced lung cancer: report of a phase I/II trial
Journal Article · Mon Feb 01 00:00:00 EST 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5436470

Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial
Journal Article · Wed Dec 01 00:00:00 EST 1982 · Cancer (Philadelphia); (United States) · OSTI ID:5436470